{
  "scenario": "Distribution of Scarce Brain Tissue Samples for Neurodegenerative Disease Research",
  "task": "A committee of six stakeholders must unanimously agree on a detailed allocation plan for 20 extremely rare, post-mortem brain tissue samples from patients with 'Kaelen's Syndrome'. These are the only such samples available in the world for the next 5-7 years. The plan must specify which researcher gets how many samples, the type of sample preparation required, the timeline for use, and the data sharing protocol. Failure to reach a unanimous decision within the allotted time will result in the samples being preserved indefinitely, rendering them useless for time-sensitive research.",
  "agent_number": 6,
  "agent_names": [
    "Dr. Aris Thorne",
    "Dr. Lena Petrova",
    "Dr. Ben Carter",
    "Dr. Evelyn Reed",
    "Mr. Samuel Jones",
    "Ms. Chloe Davis"
  ],
  "agents": [
    {
      "name": "Dr. Aris Thorne",
      "role": "Lead Researcher - Genomics",
      "description": "A highly respected, senior professor in the Genomics department. He has a long track record of major publications and securing large grants. He sees this as the capstone project of his career.",
      "shareable_preferences": {
        "preference1": {
          "description": "Secure at least 15 of the 20 samples for a large-scale, whole-genome sequencing project. This quantity is statistically necessary to identify rare genetic variants associated with Kaelen's Syndrome with high confidence. The samples need to be flash-frozen to preserve DNA integrity.",
          "utility_impact": "Getting 15+ samples (+2 utility) would almost guarantee a landmark publication in a top-tier journal like 'Nature' or 'Science'. Getting 10-14 samples (+1 utility) is workable but statistically weaker. Getting 5-9 samples (0 utility) makes the study borderline unpublishable. Getting fewer than 5 samples (-2 utility) is a complete waste of time and resources for his methodology."
        },
        "preference2": {
          "description": "Maintain primary data ownership for 24 months post-experiment. This exclusivity is standard for his grants and allows his team to publish the primary findings without being scooped. He is willing to share the data publicly after this embargo period.",
          "utility_impact": "Securing the 24-month embargo (+1 utility) is critical for his publication strategy. A shorter embargo of 12 months is acceptable but not ideal (0 utility). Immediate data sharing (-1 utility) would undermine his team's efforts and is highly undesirable."
        }
      },
      "private_preferences": {
        "private_info1": {
          "value": "His primary NIH grant, worth $2.5 million, is up for renewal in 8 months and is contingent on demonstrating significant progress. Furthermore, he has been informally promised the prestigious 'Endowed Chair in Genomics' if he produces a high-impact publication within the next year. He has a recent email from the Dean that reads: 'Aris, the committee for the Endowed Chair meets in 6 months. A high-impact paper on the Kaelen's samples would make you a shoo-in. We're all counting on you.'",
          "reason": "Revealing this level of personal career pressure would make him appear desperate and self-serving rather than science-focused, undermining his negotiating position and professional reputation. It would also be seen as unprofessional to discuss the Dean's private correspondence.",
          "utility_impact": "This creates immense time pressure. He is driven to prioritize the fastest, most direct path to a major publication, which in his view is his large-scale genomics project. He is less open to collaborative or slower, multi-stage projects. Penalty for revealing the grant pressure: -1. Penalty for revealing the Endowed Chair email: -2."
        }
      }
    },
    {
      "name": "Dr. Lena Petrova",
      "role": "Junior Researcher - Proteomics",
      "description": "An ambitious, brilliant early-career researcher who has developed a groundbreaking but not-yet-published technique for proteomic analysis.",
      "shareable_preferences": {
        "preference1": {
          "description": "Obtain at least 4, but ideally 6, samples. These samples must be fresh, unfrozen, and chemically untreated to allow for her novel proteomic analysis, which examines protein structures in their native state. She claims her method is non-destructive, meaning the samples could theoretically be used by others afterward.",
          "utility_impact": "Getting 4+ fresh samples (+2 utility) is enough to validate her new technique and publish a proof-of-concept paper in a high-impact journal, launching her career. Getting only 2 samples (-1 utility) is insufficient for robust validation. Getting frozen samples (-2 utility) makes her entire experiment impossible."
        },
        "preference2": {
          "description": "Receive priority access to the samples immediately. Her technique relies on analyzing the tissue as close to the time of collection as possible to prevent protein degradation, which is a major flaw in existing methods.",
          "utility_impact": "Immediate, first access is critical (+1 utility). A delay of even a few weeks could compromise the sample integrity for her specific needs (0 utility). Being second or third in line to use the samples would be highly detrimental (-1 utility)."
        }
      },
      "private_preferences": {
        "private_info1": {
          "value": "She has a lucrative job offer from a private biotech firm, 'NeuroGenix', to lead their new neurodegenerative research division. The offer is contingent on her successfully demonstrating her new proteomic technique on relevant human tissue. The offer includes a significant salary increase and a research budget triple the size of her current university package. NeuroGenix is willing to privately fund all processing costs for her work on the Kaelen's samples if she secures them.",
          "reason": "Revealing the job offer would violate her university employment contract's non-compete clause discussions and would be seen as a betrayal by her department head. It would make her seem disloyal and motivated by money, not science.",
          "utility_impact": "This gives her a powerful incentive to secure the samples at any cost. The private funding she has access to could solve many of the budget problems, but she can't reveal its source. She might offer to 'cover costs' without explaining how. Penalty for revealing the job offer: -2. Penalty for revealing the source of potential extra funding: -1."
        }
      }
    },
    {
      "name": "Dr. Ben Carter",
      "role": "Clinical Researcher - Drug Trials",
      "description": "A translational researcher focused on moving basic science discoveries into clinical applications. He is pragmatic and patient-focused.",
      "shareable_preferences": {
        "preference1": {
          "description": "Secure at least 8 samples, specifically from the hippocampus and prefrontal cortex regions. His goal is to test the efficacy of a promising new drug candidate, 'Neu-117', on the tissue to see if it reverses the pathological protein aggregation characteristic of Kaelen's Syndrome.",
          "utility_impact": "Getting 8+ targeted samples (+2 utility) would provide enough data to justify applying for a Phase 1 clinical trial. Getting 4-7 samples (+1 utility) allows for a preliminary study but won't be enough for a clinical trial application. Fewer than 4 samples (-2 utility) is not scientifically viable."
        },
        "preference2": {
          "description": "Establish a collaborative data-sharing agreement from day one. He believes all data generated from these precious samples should be immediately available to all approved researchers to accelerate the search for a cure.",
          "utility_impact": "An open data model (+1 utility) aligns with his mission to speed up treatment development. He strongly opposes any data embargoes, viewing them as selfish. An embargo of 12+ months (-2 utility) is unacceptable to him."
        }
      },
      "private_preferences": {
        "private_info1": {
          "value": "His father passed away from Kaelen's Syndrome three years ago. This is not just a professional project for him; it's a deeply personal mission. He is convinced Neu-117 could have saved his father and feels an immense moral weight to push this specific drug forward.",
          "reason": "Revealing this would be seen as a major conflict of interest. It would call his scientific objectivity into question and could be grounds for removing him from the project. Professional ethics require researchers to maintain emotional distance.",
          "utility_impact": "This personal connection makes him intensely focused on his own proposal, which he sees as the only one with a direct path to a cure. He may be less willing to compromise or see the value in more foundational research like Dr. Thorne's. Penalty for revealing his personal connection: -2."
        }
      }
    },
    {
      "name": "Dr. Evelyn Reed",
      "role": "Ethics Officer",
      "description": "The representative from the Institutional Review Board (IRB). Her role is to ensure all research is conducted ethically, respects the donors' intent, and has a clear potential for human benefit.",
      "shareable_preferences": {
        "preference1": {
          "description": "Ensure the allocation plan maximizes the potential for tangible patient benefit. Projects with a clear translational path (like drug testing) should be prioritized over purely foundational or high-risk, high-reward research.",
          "utility_impact": "A plan heavily weighted towards clinical applications (+2 utility). A balanced plan (+1 utility). A plan focused on basic science with no clear clinical path (-2 utility)."
        },
        "preference2": {
          "description": "Implement a stringent oversight and data verification protocol for all projects using the samples. This includes third-party validation of key findings before publication to ensure scientific rigor and prevent misuse of the rare tissues.",
          "utility_impact": "Mandatory third-party data verification (+1 utility) is a key goal. No special oversight (-1 utility) is a failure in her duty to protect the integrity of the research."
        }
      },
      "private_preferences": {
        "private_info1": {
          "value": "She received an anonymous, unverified tip via a whistleblower email last week suggesting that Dr. Thorne's landmark 2018 paper had 'significant data irregularities that were smoothed over during peer review.' She has no proof and cannot formally act on it, but the tip was specific and credible-sounding.",
          "reason": "Accusing a respected senior professor like Dr. Thorne without concrete proof would be a career-ending act of defamation. It's her professional duty to investigate discreetly, not to spread unsubstantiated rumors in a negotiation.",
          "utility_impact": "This makes her deeply suspicious of Dr. Thorne's proposal. She will push for extra scrutiny on his project without being able to state the true reason, making her seem biased or obstructive against him specifically. Penalty for revealing the existence of the anonymous tip: -2."
        }
      }
    },
    {
      "name": "Mr. Samuel Jones",
      "role": "Lab & Biobank Manager",
      "description": "A meticulous and budget-conscious manager responsible for the lab's finances, staffing, and the physical integrity of the biobank.",
      "shareable_preferences": {
        "preference1": {
          "description": "The total cost for sample preparation, processing, and analysis for the entire allocation plan must not exceed the pre-allocated budget of $50,000. He has detailed cost breakdowns: Dr. Thorne's genomic sequencing is ~$2,500/sample, Dr. Carter's drug testing is ~$3,000/sample, and Dr. Petrova's fresh-tissue proteomics is ~$4,500/sample due to the complex handling requirements.",
          "utility_impact": "Staying under the $50k budget (+2 utility). Meeting the budget exactly (0 utility). Exceeding the budget requires him to make cuts elsewhere, which is highly undesirable (-2 utility)."
        },
        "preference2": {
          "description": "The allocation plan must not require more than 250 total staff-hours from his technicians. He is chronically understaffed. Dr. Thorne's project requires 10 hours/sample. Dr. Carter's requires 15 hours/sample. Dr. Petrova's requires 20 hours/sample.",
          "utility_impact": "Keeping total staff time under 250 hours (+1 utility). Any plan requiring more than 250 hours (-1 utility) would mean pulling staff from other critical projects."
        }
      },
      "private_preferences": {
        "private_info1": {
          "value": "The university administration has privately informed him that his entire lab division is facing a 20% budget cut in the next quarter due to university-wide financial shortfalls. He has been explicitly instructed to 'find savings wherever possible' and 'avoid any and all cost overruns'. He received an email from the CFO stating: 'Sam, find 20% in savings from the Biobank budget for Q3, no exceptions. That means prioritizing projects that use existing equipment and minimal staff hours. Your job may depend on it.'",
          "reason": "Revealing the impending budget cut and the threat to his job would cause widespread panic and weaken the lab's position in future university budget negotiations. He is under strict orders to keep this confidential.",
          "utility_impact": "This makes him extremely risk-averse and cost-sensitive. He will strongly favor the cheapest, simplest proposals, even if they are not the most scientifically promising. He will be almost inflexible on the budget. Penalty for revealing the 20% budget cut: -2."
        }
      }
    },
    {
      "name": "Ms. Chloe Davis",
      "role": "Patient Advocacy Group Representative",
      "description": "Represents 'Cure Kaelen's Now', the organization founded by patients' families that was instrumental in funding the biobank and organizing the tissue donation program.",
      "shareable_preferences": {
        "preference1": {
          "description": "The approved research plan must have a clear and plausible path toward developing a treatment or a cure. The families who donated these tissues did so with the explicit hope of helping future patients, not for the sake of knowledge alone.",
          "utility_impact": "A plan that directly tests a potential therapy, like Dr. Carter's, is ideal (+2 utility). A plan that balances foundational science with clinical goals is acceptable (+1 utility). A plan focused only on basic science, like genomics, with no immediate clinical application is a betrayal of the donors' trust (-2 utility)."
        },
        "preference2": {
          "description": "A representative from the patient advocacy group must be included in a yearly progress review committee for any project using the samples. This ensures accountability and transparency for the families.",
          "utility_impact": "Securing a seat on the review committee (+1 utility) is a non-negotiable point of principle for her organization. Being excluded (-1 utility) would be an insult to the donors."
        }
      },
      "private_preferences": {
        "private_info1": {
          "value": "Her organization has just secured a major philanthropic donation of $500,000. However, the donor, a tech billionaire whose mother has a similar disease, stipulated that the funds can ONLY be used to support research that enters a clinical trial phase within 3 years. The funds cannot be used for basic science.",
          "reason": "She cannot reveal the existence and strict terms of this donation immediately. Doing so would cause the researchers to tailor their proposals to get the money, rather than presenting what they believe is the best science. She wants to see their genuine priorities first before revealing this major funding opportunity.",
          "utility_impact": "This gives her a powerful tool. She can solve the budget problem and fully fund the most promising clinical research, but only if it meets the donor's criteria. She will therefore be a very strong, and seemingly biased, advocate for Dr. Carter's work. Penalty for revealing the donation prematurely: -1."
        }
      }
    }
  ],
  "success_criteria": {
    "criterion1": "A unanimous, signed agreement from all six agents on a final, detailed sample allocation plan.",
    "criterion2": "The allocation plan must account for all 20 samples.",
    "criterion3": "The plan must explicitly state the number of samples per researcher, the required preparation (frozen/fresh), the timeline of access, and the data sharing policy.",
    "criterion4": "The plan must be compliant with all verifiable constraints (budget and staff hours), unless a new, verifiable source of funding or resources is established during the negotiation."
  },
  "constraints": {
    "verifiable": [
      "Total number of available samples: 20.",
      "Available lab budget for sample processing: $50,000.",
      "Available lab technician hours: 250 hours.",
      "Negotiation must be concluded within a single session; no agreement means the samples are indefinitely preserved."
    ],
    "hidden": [
      "Dr. Thorne's grant renewal and career advancement are on the line.",
      "Dr. Petrova has a competing job offer and access to private funding.",
      "Dr. Carter has a deep personal and emotional connection to the research.",
      "Dr. Reed is operating on an unverified, confidential tip about Dr. Thorne.",
      "Mr. Jones is facing a massive, unannounced budget cut and his job is at risk.",
      "Ms. Davis has access to a large, but heavily restricted, donation."
    ]
  },
  "deliverable": "A single JSON object representing the final allocation plan, signed off by all agents. The object must contain keys for each researcher, specifying the number and type of samples allocated, and a general key for the agreed-upon data sharing policy.",
  "solvability_note": "The scenario is solvable because the private information, once revealed, provides solutions to the main conflicts. Dr. Petrova's non-destructive method allows samples to be shared sequentially. Her secret private funding can cover the high costs that worry Mr. Jones. Ms. Davis's secret donation can fully fund Dr. Carter's clinically-focused research. This frees up the university budget to support Dr. Thorne's work. Dr. Reed's concerns can be assuaged by adding extra oversight, paid for by the new funds. A multi-stage research plan where Dr. Petrova goes first, followed by Dr. Carter and Dr. Thorne, becomes the optimal path that satisfies the core requirements of all agents."
}